Glenmark launches drug for the treatment of seizures

It is indicated for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) along with other medicines

43
Medicine
Picture: Pixabay

Glenmark Pharmaceuticals has launched Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel Tablets, 200 mg and 400 mg of Eisai. Glenmark received final approval for Rufinamide Tablets on May 16, 2016.

It is indicated for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) along with other medicines

Commenting on the launch, Sanjeev Krishan, President, Glenmark North America said, “We are very pleased to be one of the first generic companies in the US to offer lower cost alternative to Banzel Tablets, 200 mg and 400 mg. The launch is our commitment to provide quality and affordable healthcare to our markets for patients.”

According to IQVIA sales data for the 12 month period ending April 2021, the Banzel Tablets, 200 mg and 400 mg market achieved annual sales of approximately $285.3 million*.

Glenmark’s current portfolio consists of 172 products authorised for distribution in the US marketplace and 45 ANDA’s pending approval with the USFDA.

Celon launches an emulsion-based drug to treat Black Fungus

JB Chemicals launches medicated Nicotine lozenges: Quit smoking

Merck launches synthetic cholesterol product

BDR Pharma launches generic Rucaparib

Bal Pharma launches Favipiravir tablets in India

Zydus Cadila launches drug for Breast cancer treatment

PLI Scheme: Approvals accorded for Promotion of APIs

DCGI issues safety alerts on Medical Devices

JB Chemicals launches medicated Nicotine lozenges: Quit smoking

Modern Lab to produce Amphotericin B Inj to treat black fungus

Celon launches an emulsion-based drug to treat Black Fungus

Take care of your Air, Don’t share it

Subscribe for daily free updates on Telegram

Follow us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Enter your email address:

Delivered by FeedBurner